Abiopharma

(99% Neutral) INNOVAGE HOLDING CORP (INNV) Announces New Board Appointment

SciSparc Notification (SPRC)

BioLife Solutions to Report Third Quarter 2025 Financial Results and Business Update on November 6, 2025

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

(99% Neutral) Intensity Therapeutics, Inc. (INTS) Announces Regulatory Update

📋 MARY REUMUTH (Officer) plans to sell 967 shares of KALA BIO, Inc. (at $0.82 each, total $793.21) Filed: Oct 23, 2025 | ID: 008125

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

Semler Scientific Inc. (SMLR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LifeMD, Inc. (LFMD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit